Pharmaceutical

BridgeBio secures $1.25bn for genetic therapy development

BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.

Jan 19, 2024 - 18:00
BridgeBio secures $1.25bn for genetic therapy development
BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.
Read the original article

Tags:

Previous Article

FDA grants fast track designation for Verastem’s NSCLC therapy

Next Article

argenx’s VYVDURA gains approval in Japan for gMG treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BIOSECURE “grandfather” amendment softens impact of US-China trade ban

BIOSECURE “grandfather” amendment softens impact of US-...

May 31, 2024

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT+: Pharma loses a key battle over a state law conce...

Mar 13, 2024

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

Listen: Biotech’s monkey shortage, the broken generics ...

Mar 30, 2023